Drug Search Results
More Filters [+]

Tirofiban

Alternative Names: tirofiban, aggrastat
Latest Update: 2024-09-16
Latest Update Note: Clinical Trial Update

Product Description

Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa receptor antagonist which specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times in patients with acute coronary syndromes. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/9878994/)

Mechanisms of Action: GPIIb/IIIa Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Medicure
Company Location: WINNIPEG A2 R3T 6C6
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tirofiban

Countries in Clinic: China

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Ischemic Stroke

Phase 2: Acute Coronary Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ADJUVANT

P3

Recruiting

Ischemic Stroke

2027-03-01

RESET

P2

Active, not recruiting

Ischemic Stroke

2023-03-30

CTR20132880

P2

Active, not recruiting

Acute Coronary Syndrome

None

CTR20213126

P2

Not yet recruiting

Ischemic Stroke

None

Recent News Events